ERBB2 and gastric cancer: The open-label, randomized, phase II DESTINY-Gastric01 trial (ClinicalTrials.gov identifier NCT03329690) compared the efficacy and safety of 6.4 mg/kg of DXd every 21 days with standard therapies in patients with HER2-positive gastric cancer who had received ≥2 prior treatment regimens [39].